AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Chart showing rapid growth/iStock, Geerati

Biologics Projected to Keep Gaining Ground in Cancer Therapeutics Market

The market size for biologic oncology therapies will reach $786 billion by 2029, far outstripping small molecules, a GlobalData report predicts.

November 20, 2023

4 min read

Patience Asanga

Update: AbbVie headquarters building in California

Drug Development

AbbVie’s Migraine Drug Ubrelvy Scores Victory in Phase III Study

When given hours ahead of an expected episode, a late-stage study showed the preventive benefits of Ubrelvy in safely reducing moderate or severe headaches within 24 hours of treatment.

November 17, 2023

2 min read

Tristan Manalac

Pictured: AbbVie Corporate Office/iStock, vzphotos

Drug Development

AbbVie’s Skyrizi Beats Remission Rates of J&J’s Stelara in Crohn’s Disease

In a follow-up readout, data from the head-to-head SEQUENCE study showed that AbbVie’s Skyrizi induced better rates of steroid-free remission in Crohn’s disease than Johnson & Johnson’s Stelara.

October 17, 2023

2 min read

Tristan Manalac

Pictured: American cash shaped into a funnel/iStoc

Deals

Early October Sees Torrid Pace of Biotech M&A—Will It Continue?

The first two weeks of October saw BMS’s $4.8 billion buyout of Mirati, Lilly’s $1.4 billion purchase of Point, Kyowa Kirin’s $387 million acquisition of Orchard and AbbVie’s $110 million Mitokinin deal.

October 13, 2023

2 min read

Greg Slabodkin

Pictured: Federal Trade Commission Sign/Courtesy o

Business

Pharma Companies Form Coalition to Fight FTC Antitrust Overhaul

AbbVie, Amgen, Gilead, Merck and Novartis are among the 31 members that have formed the Partnership for the U.S. Life Science Ecosystem to push back against federal antitrust reforms.

October 4, 2023

2 min read

Connor Lynch

Business

AbbVie Terminates Caribou CAR-T Contract in Culling of Cancer Pipeline

Soon after cancelling its contract with I-Mab, AbbVie has now also turned its back on a partnership with Berkeley-based Caribou Biosciences that was focused on advancing allogeneic CAR-T therapeutics.

September 27, 2023

2 min read

Tristan Manalac

Business

AbbVie Ends I-Mab Deal for CD47 Antibody Compounds, Products

After dropping an early-stage study more than a year ago, AbbVie has finally terminated its CD47 collaboration with I-Mab, leaving up to $1.3 billion in potential milestone payments on the table.

September 25, 2023

2 min read

Tristan Manalac

Pictured: Series of outcroppings with steep cliffs

Drug Development

Biotech Financing, IPO Tide May Be Turning – Signs of a Potential Recovery?

In the largest biotech Series C financing so far this year, Generate:Biomedicines raised $273 million, while Neumora and RayzeBio announced IPO pricing valued at more than $560 million combined.

September 15, 2023

2 min read

Greg Slabodkin

Business

AbbVie Passes on License Option for Harpoon’s TriTAC Multiple Myeloma Program

The company declined to exercise the license option for Harpoon Therapeutics’ TriTAC HPN217 program for multiple myeloma, which targets B cell maturation antigen, or BCMA.

September 14, 2023

2 min read

Tristan Manalac

JOBS